Antimicrobial compositions containing cationic active ingredients
AssigneeEcolab USA Inc.
InventorsDaniel E. Pedersen, Carter M. Silvernail, Kerrie E. Walters, Hilina Emiru
Life of this patent
Estimating the term…
Abstract
The antimicrobial composition of the present invention comprises a cationic active ingredient, a foam boosting surfactant, a foam boosting copolymer, a foam stabilizer, and a chelating agent. The present antimicrobial compositions are free of the antimicrobial agent triclosan (i.e., 2,4,4′-trichloro-2′hydroxy-diphenylether), have rapid cidal activity, provide stable copious foam and exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.
Claims8
A method of reducing bacterial, microbial, fungicidal or viral population on a dermal tissue of a mammal under hard water conditions comprising the step of:
- diluting a dermal concentrate with water to form a use solution with a concentrate to water ratio of from about 1:3 to about 1:8;
- and
- contacting the dermal tissue of a mammal with the use solution for a period of contact time to provide substantial bacterial, microbial, fungicidal or viral reduction,
- wherein the dermal concentrate comprises:
- (a) from about 0.1 to about 10 wt. % of a cationic active ingredient, wherein the cationic active ingredient is an inorganic salt of an aromatic quaternary ammonium containing compound;
- (b) from about 0.1% to about 4.5% of a quaternized sugar-derived surfactant;
- (c) from about 17 wt-% to about 25 wt. % of a foam boosting amine oxide surfactant composition;
- (d) from about 0.05 wt. % to about 18 wt. % of a foam boosting copolymer, wherein the foam boosting copolymer is a dimethyldiallylammonium chloride-acrylamide copolymer, wherein said dimethyldiallylammonium chloride-acrylamide copolymer has a molecular weight from about 500,000 to about 5,000,000 g/mol;
- (e) from about 2 wt. % to about 4 wt. % of a foam stabilizing, linear or branched C5-12 diol with the structure
- wherein R1=H, CH3, CH2CH3, CH2CH2CH3, C(CH3)3, CH(CH3)2 or combinations thereof and R2 is a branched or linear C1-C9 alkyl chain;
- (f) from about 0.1 wt. % to about 6.0 wt. % of an aminocarboxylate chelating agent, wherein said chelating agent is ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), methylglycine-N,N-diacetic acid (MGDA), glutamic acid-N,N-diacetic acid (GLDA), or aspartic acid-N,N-diacetic acid (ASDA) or alkali metal or ammonium salts thereof;
- and
- (g) water,
- wherein said dermal concentrate is substantially free of anionic surfactants, a substituted phenol compound, and C1-4 alcohols, and wherein said dermal concentrate exhibits antimicrobial efficacy against both gram positive and gram negative bacteria.
A method of reducing bacterial, microbial, fungicidal or viral population on a dermal tissue of a mammal under hard water conditions comprising the step of:
- contacting the dermal tissue of a mammal with a use solution of a dermal concentrate for a period of a contact time to provide substantial bacterial, microbial, fungicidal or viral reduction,
- wherein the use solution is formed by diluting the dermal concentrate with water in a ratio of from about 1:3 to about 1:8,
- wherein the dermal concentrate comprises:
- (a) from about 0.1 to about 10 wt. % of a cationic active ingredient, wherein the cationic active ingredient is an inorganic salt of an aromatic quaternary ammonium containing compound;
- (b) from about 0.1% to about 4.5% of a quaternized sugar-derived surfactant;
- (c) from about 17 wt-% to about 25 wt. % of a foam boosting amine oxide surfactant composition;
- (d) from about 0.05 wt. % to about 18 wt. % of a foam boosting copolymer, wherein the foam boosting copolymer is a dimethyldiallylammonium chloride-acrylamide copolymer, wherein said dimethyldiallylammonium chloride-acrylamide copolymer has a molecular weight from about 500,000 to about 5,000,000 g/mol;
- (e) from about 2 wt. % to about 4 wt. % of a foam stabilizing, linear or branched C5-12 diol with the structure
- wherein R1=H, CH3, CH2CH3, CH2CH2CH3, C(CH3)3, CH(CH3)2 or combinations thereof and R2 is a branched or linear C1-C9 alkyl chain;
- (f) from about 0.1 wt. % to about 6.0 wt. % of an aminocarboxylate chelating agent, wherein said chelating agent is ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), methylglycine-N,N-diacetic acid (MGDA), glutamic acid-N,N-diacetic acid (GLDA), or aspartic acid-N,N-diacetic acid (ASDA), or alkali metal or ammonium salts thereof;
- and
- (g) water,
- wherein said dermal concentrate is substantially free of anionic surfactants, a substituted phenol compound, and C1-4 alcohols, and wherein said dermal concentrate exhibits antimicrobial efficacy against both gram positive and gram negative bacteria.
Dependencies are inferred from the claim text.